Synthesis and biological evaluation of benzamide‐chalcone hybrids as potential c‐Met kinase and COX‐2 inhibitors

Abstract c‐Met kinase and cyclooxygenase 2 (COX‐2) enzymes are two significant targets in tumor progression. Chalcone and benzamide moieties were combined using molecular hybridization to assess their potential as c‐Met kinase and COX‐2 inhibitors. 4‐Methylbenzamide and 4‐chlorobenzamide chalcone analogs were synthesized, characterized, and evaluated for antiproliferative activity on Michigan Cancer Foundation‐7 (MCF‐7), HT‐29, MDA‐MB‐231, COLO‐205, and A549 cell lines by sulforhodamine‐B stain (SRB) assay. Following the SRB assay, compounds were evaluated for their c‐Met kinase and COX‐2 inhibitory potential. All compounds inhibited COX‐2 with half‐maximal inhibitory concentration (IC 50 ) <10 µM. Compounds 7h , 7i , 7j , 8f , and 8j inhibited c‐Met with IC 50 <10 µM. Compound 7h was evaluated for its long‐term antiproliferative and anti‐migratory effects by colony formation and wound healing assay. It exerted these effects in a concentration‐dependent manner. Compounds 7j and 8j were further evaluated for in vitro antiangiogenic effects. Compound 7j exhibited moderate antiangiogenic effect while compound 8j exhibited strong effect. Compounds 7h , 7i , 7j , 8f , and 8j were evaluated for the serum protein binding, using the in vitro bovine serum albumin binding assay. The results indicated that the tested compounds bind to bovine serum albumin (BSA) and can be further explored by other studies.